Capillary permeability is increased in normo- and microalbuminuric type 1 diabetic patients: amelioration by ACE-inhibition

Eur J Clin Invest. 1999 Dec;29(12):1035-40. doi: 10.1046/j.1365-2362.1999.00568.x.

Abstract

Background: Capillary leakage of sodium-fluorescein (NaF) in the skin reflects capillary permeability and may be a marker of diabetes-associated microcirculatory abnormalities.

Design: We evaluated transcapillary skin NaF leakage by fluorescence videodensitometry in 10 normoalbuminuric, 10 microalbuminuric Type 1 diabetic men (diabetes duration > 10 years) and 10 healthy subjects. The microalbuminuric patients were restudied after 6 weeks treatment with the ACE-inhibitor enalapril, 10 mg once daily. All measurements were performed at a blood glucose level of 5 mmol L-1.

Results: Transcapillary NaF leakage was strongly increased in normoalbuminuric Type 1 diabetic patients compared to healthy subjects (P < 0.001) and was still further increased in microalbuminuric Type 1 diabetic patients (P < 0.01 compared to normoalbuminuric patients). Enalapril reduced NaF leakage (P < 0.05), mean arterial blood pressure (P < 0.05) and microalbuminuria (P < 0. 05). After treatment, NaF leakage was not different from that in normoalbuminuric patients.

Conclusions: Capillary permeability, as determined by NaF leakage, is elevated in normoalbuminuric Type 1 diabetic patients with long-standing disease, and the excess elevation in microalbuminuric Type 1 diabetic patients is ameliorated by ACE-inhibition. Skin NaF videodensitometry seems a useful tool to document capillary permeability in intervention studies.

Publication types

  • Clinical Trial

MeSH terms

  • Albuminuria / drug therapy
  • Albuminuria / etiology
  • Albuminuria / metabolism*
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Blood Glucose / metabolism
  • Capillary Permeability / drug effects*
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / metabolism*
  • Enalapril / pharmacology
  • Enalapril / therapeutic use*
  • Fluorescein / pharmacokinetics
  • Humans
  • Microcirculation / drug effects
  • Middle Aged
  • Skin / metabolism

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Blood Glucose
  • Enalapril
  • Fluorescein